

Edgar Filing: REPLIGEN CORP - Form 8-K

REPLIGEN CORP
Form 8-K
September 17, 2003

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) September 16, 2003

REPLIGEN CORPORATION

(Exact name of registration as specified in charter)

Delaware (State or other jurisdiction of incorporation)	0-14656 (Commission File Number)	04-2729386 (IRS Employer Identification No.)
--	--	--

41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA (Address of principal executive offices)	02453 (Zip Code)
--	---------------------

Registrant's telephone number, including area code (781) 250-0111

(Former name or former address, if changed since last report.)

Item 5. Other Events and Required FD Disclosure.

Repligen Corporation (Nasdaq: RGEN) announced on September 16, 2003 that it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering the use of CTLA4-Ig for the treatment of rheumatoid arthritis. A press release announcing the receipt of the Notice of Allowance is attached hereto as Exhibit 99.1.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits.

Exhibit No. -----	Exhibit -----
99.1	Press Release dated September 16, 2003.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the

Edgar Filing: REPLIGEN CORP - Form 8-K

undersigned hereunto duly authorized.

Repligen Corporation

Dated: September 17, 2003

By: /s/ Walter C. Herlihy

Walter C. Herlihy
Chief Executive Officer and President

EXHIBIT INDEX

Exhibit No.

Exhibit

99.1

Press Release dated September 16, 2003.